Speech in Commons Chamber - Tue 29 Oct 2019
Oral Answers to Questions
"Health service professionals in the Black Country are concerned that the removal of local funding for in-house molecular testing for cancer in April in favour of regional genomic laboratory hubs could in certain circumstances cause delays in diagnosis and be more expensive. Will the Minister look at this again in …..."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Oral Answers to Questions
Speech in Westminster Hall - Mon 10 Jun 2019
Cystic Fibrosis Drugs: Orkambi
"Order. Seventeen would-be speakers are listed for the debate. Back-Bench contributions will conclude at 6.58 pm to allow for the Front-Bench speeches and the proposer’s summing up. I will therefore put a six-minute time limit on individual contributions. I call Kerry McCarthy...."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Cystic Fibrosis Drugs: Orkambi
Speech in Westminster Hall - Mon 10 Jun 2019
Cystic Fibrosis Drugs: Orkambi
"I gave the Chair of the Select Committee a little latitude, but that may not be available to other speakers. I call Sir Mike Penning...."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Cystic Fibrosis Drugs: Orkambi
Speech in Commons Chamber - Tue 14 May 2019
Health
"My hon. Friend is making an excellent case. In my local authority, Sandwell, life expectancy is in the bottom 15% nationally and the childhood obesity rate is more than three times that of the best local authorities, yet although nationally the Government boast that they are investing money in the …..."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Health
Written Question
Tuesday 26th March 2019
Asked by:
Adrian Bailey (Labour (Co-op) - West Bromwich West)
Question
to the Department of Health and Social Care:
What recent progress has been made on the treatment of myalgic encephalomyelitis.
Answered by Caroline Dinenage
In September 2017, the National Institute for Health and Care Excellence announced its plans for a full update to the existing clinical guideline on the diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) to ensure that treatment reflects the latest available evidence. The revised guideline will be published in 2020.
Since 2011, we have also invested £6 million into research into CFS/ME via the Medical Research Council and the National Institute for Health Research.
Speech in Commons Chamber - Tue 26 Mar 2019
Oral Answers to Questions
"In a debate on 24 January in this Chamber, many contributors outlined the dangers of using graded exercise therapy in treating ME. What conversations has the Department had with NICE on that issue before the proposed publication of the revised treatment guidelines in October 2020?..."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Oral Answers to Questions
Written Question
Thursday 28th February 2019
Asked by:
Adrian Bailey (Labour (Co-op) - West Bromwich West)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the planned timescale is for patients to access Spinraza treatment for muscular atrophy types 2 and 3.
Answered by Steve Brine
The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.
NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE’s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.
Written Question
Thursday 28th February 2019
Asked by:
Adrian Bailey (Labour (Co-op) - West Bromwich West)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress has been made on concluding a managed access treatment agreement for the use of Spinraza for patients with spinal muscular atrophy types 2 and 3.
Answered by Steve Brine
The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.
NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE’s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.
Speech in Westminster Hall - Wed 27 Feb 2019
Eating Disorders Awareness Week
"I call Louise Haigh...."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Eating Disorders Awareness Week
Speech in Westminster Hall - Wed 27 Feb 2019
Eating Disorders Awareness Week
"Before I move on to the other speakers, I point out for the record that the intervention was made by Rachael Maskell, not Louise Haigh, her close friend. However, I noticed that she did not notice; confusion reigns. I call Paul Farrelly...."Adrian Bailey - View Speech
View all Adrian Bailey (LAB - West Bromwich West) contributions to the debate on: Eating Disorders Awareness Week